Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
Advisory board to help guide selection of novel antibody-target pairs for ADC and T cell redirection modalities
News
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease
The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries
Annovis Currently has 50 Clinical Trial Sites Open in the United States
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study
Starting in early 2023 the biopharmaceutical company will use the Strados RESP™ Biosensor to remotely monitor cough and crackles in patients at home.
Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease
Strong enrollment in Phase 3 trial demonstrates continued execution
Interim analysis expected in 2Q 2023
iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis
Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time
First-of-its-kind technology stack in autoimmune diseases.
Provides unprecedented insights into optimal patient treatment pathway.
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
– Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine
– Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties